Why Apellis Pharmaceutical Shares Are Plunging Today

Apellis Pharmaceuticals Inc APLS is trading lower Friday after the company announced its Phase 3 DERBY study in geographic atrophy did not meet the primary endpoint of GA lesion growth.

DERBY did not meet the primary endpoint by itself, but the company said, in a prespecified analysis of the combined DERBY and OAKS studies, monthly and every-other-month treatment with pegcetacoplan reduced GA lesion growth by 17%.

Analyst Assessment: Multiple analyst firms lowered price targets on the stock following the results:

  • Needham analyst Joseph Stringer maintained Apellis with a Buy rating and lowered the price target from $85 to $70.
  • BMO Capital analyst Matthew Luchini maintained Apellis with an Outperform rating and lowered the price target from $89 to $69.
  • Wedbush analyst Laura Chico downgraded Apellis from Outperform to Neutral and lowered the price target from $71 to $39.
  • Credit Suisse analyst Tiago Fauth maintained Apellis with a Neutral rating and lowered the price target from $50 to $38.
  • Roth Capital analyst Elemer Piros maintained Apellis with a Buy rating and lowered the price target from $80 to $46.

Apellis is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system.

APLS Price Action: Apellis has traded as high as $73 and as low as $27.50 over a 52-week period.

The stock was down 39.3% at $33.78 at time of publication.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: NewsPrice TargetAnalyst RatingsCedric Francoiswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!